Photodynamic Therapy for PDA in NV AMD

Completed

Conditions studied: Neovascular Age-related Macular Degeneration, Macular Degeneration

In brief

The purpose of this prospective observational study is to assess the potential clinical effects of adjunctive verteporfin photodynamic therapy (PDT) for persistent disease activity among patients with neovascular age-related macular degeneration (NV AMD). No specific interventions will occur as part of the study; participating subjects undergoing PDT as part of standard-of-care will be asked to consent to prospective collection of data from their medical records for up to five years from the date of consent, including results from ophthalmologic exams, imaging, and treatments. The primary study outcome will be the percentage of subjects with resolution of persistent disease activity at six months post-PDT treatment. Aside from a small risk of loss of confidentiality, risks associated with this study are no greater than those related to standard of care.

Key facts

Study ID

NCT02452840

Run by

Duke University

People needed

100

Starts

2015-05-11

Expected to finish

2019-08-01

Last updated by the study team

2021-11-09

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of NV AMD
• Evidence of PDA in spite of loading dose intravitreal anti-VEGF therapy. PDA is defined as (1) unresolved intraretinal, subretinal, or sub-retinal pigment epithelium fluid; (2) progressive lesion enlargement and fibrosis; and/or (3) persistent or new hemorrhage.
• Undergoing adjunctive verteporfin PDT for the treatment of PDA
• Able to give written informed consent

You may not qualify if…

• Prior PDT treatment

Where it is running

• Duke Eye Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.